{"disease":{"id":"classical-hodgkin-lymphoma","name":"Classical Hodgkin lymphoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":8},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Classical Hodgkin lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"immuno-oncology-io","indication_name":"Classical Hodgkin Lymphoma (cHL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"pembrolizuma","indication_name":"Classical Hodgkin lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02684708","title":"Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2921,"lead_sponsor_name":"University of Giessen","has_results":false},{"nct_id":"NCT03327571","title":"B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":1770,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04858568","title":"Immune Responses to COVID-19 Vaccination in Lymphoma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":592,"lead_sponsor_name":"University Hospital Southampton NHS Foundation Trust","has_results":false},{"nct_id":"NCT05934084","title":"Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors","phase":"NA","overall_status":"RECRUITING","enrollment_count":552,"lead_sponsor_name":"Fondazione Italiana Linfomi - ETS","has_results":false},{"nct_id":"NCT02332668","title":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":370,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03527628","title":"OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":220,"lead_sponsor_name":"King Abdullah International Medical Research Center","has_results":false},{"nct_id":"NCT05008224","title":"Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02815137","title":"Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"Centre Henri Becquerel","has_results":false},{"nct_id":"NCT04254107","title":"A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":133,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT00742027","title":"Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03042247","title":"Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Marco Picardi","has_results":false},{"nct_id":"NCT03004833","title":"Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT03580564","title":"An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06393361","title":"Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06563778","title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03114683","title":"Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":true},{"nct_id":"NCT06563245","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Children's Cancer Group, China","has_results":false},{"nct_id":"NCT02414568","title":"Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"The Lymphoma Academic Research Organisation","has_results":false},{"nct_id":"NCT07450508","title":"Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT03655483","title":"Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":85,"lead_sponsor_name":"Guangzhou Gloria Biosciences Co., Ltd.","has_results":false},{"nct_id":"NCT03657381","title":"Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Shandong New Time Pharmaceutical Co., LTD","has_results":false},{"nct_id":"NCT06848569","title":"Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":73,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03209973","title":"A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT06504394","title":"A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07171827","title":"Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Helwan University","has_results":false},{"nct_id":"NCT04067037","title":"Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT04342936","title":"Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":56,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05900765","title":"A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05140382","title":"AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03331341","title":"Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT04318080","title":"Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT05216835","title":"Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05404945","title":"Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT04510636","title":"Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06814860","title":"Microenvironmental Trial of Classical Hodgkin Lymphoma in Adolescents","phase":"","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03190174","title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Sarcoma Oncology Research Center, LLC","has_results":true},{"nct_id":"NCT05683704","title":"Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03480334","title":"Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":26,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT06617286","title":"CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":21,"lead_sponsor_name":"New York Medical College","has_results":false},{"nct_id":"NCT05714553","title":"NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"NuCana plc","has_results":false},{"nct_id":"NCT04288726","title":"Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT02940301","title":"Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05352828","title":"Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Tessa Therapeutics","has_results":false},{"nct_id":"NCT03652441","title":"Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT03229278","title":"Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT02981914","title":"Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT03236935","title":"Phase Ib of L-NMMA and Pembrolizumab","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"The Methodist Hospital Research Institute","has_results":true},{"nct_id":"NCT04187872","title":"LITT and Pembrolizumab in Recurrent Brain Metastasis","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT06018129","title":"A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Genmab","has_results":true},{"nct_id":"NCT06870487","title":"A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Pfizer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}